Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TXN | P10599 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748623 | 0.91 | ROCK1 (0.55) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL11837292 | 0.80 | NFKB1 (0.78) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL10668863 | 0.79 | RAB9A (0.51) | MAPTSMN1; SMN2KDM4EROCK1MEN1 | |
| SCHEMBL1390681 | 0.77 | MAPT (0.93) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL8909947 | 0.77 | CHRNA7 (0.72) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL21381268 | 0.75 | NFKB1 (0.70) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL21645541 | 0.74 | TXN (0.89) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL1658574 | 0.74 | TXN (0.89) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL3500246 | 0.74 | NFKB1 (0.69) | MAPTSMN1; SMN2NFKB1KDM4ETXN | |
| SCHEMBL8973510 | 0.74 | MAPT (1.00) | MAPTSMN1; SMN2NFKB1KDM4EAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | MAPT 4579/4885SMN1; SMN2 2921/4885NFKB1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.